Evolus (Evolus) Interest Expense : $-13.8 Mil (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Evolus Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Evolus's interest expense for the three months ended in Dec. 2023 was $ -4.1 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-13.8 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Evolus's Operating Income for the three months ended in Dec. 2023 was $ -9.5 Mil. Evolus's Interest Expense for the three months ended in Dec. 2023 was $ -4.1 Mil. Evolus did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Evolus Interest Expense Historical Data

The historical data trend for Evolus's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus Interest Expense Chart

Evolus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-7.95

-10.50

-1.40

-9.10

-13.83

Evolus Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-2.63	-2.79	-3.18	-3.79	-4.08

Evolus Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.8 Mil.

Evolus (NAS:EOLS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Evolus's Interest Expense for the three months ended in Dec. 2023 was $-4.1 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-9.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $125.2 Mil.

Evolus's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Evolus did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Evolus (Evolus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (NAS:EOLS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

EVL:Germany EVL:Germany

Address

520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660

Website

https://www.evolus.com

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary of 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare, or commercial insurance. It generates product revenue from the sale of Jeuveau in the United States.

Executives

David Moatazedi	director, officer: See Remarks	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Medytox Inc.	10 percent owner	78, GANGNI 1-GIL, OCHANG-EUP,, CHEONGWON-GU, CHEOGJU-SI M5 28126
Sandra Beaver	officer: Chief Financial Officer	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Tomoko Yamagishi-dressler	officer: Chief Marketing Officer	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Rui Avelar	officer: See Remarks	1618 STATION STREET, VANCOUVER A1 V6A 1B6
Vikram Malik	director	17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
Alphaeon 1 Llc	10 percent owner	4040 MACARTHUR BOULEVARD, SUITE 310, NEWPORT BEACH CA 92660
Robert Hayman	director	8550 HIGUERA ST, CULVER CITY CA 90232
Simone Blank	director	C/O SIRONA, WASSERFELDSTRASSE 30 A-5020, SALZBURG C4 5020
Peter C Farrell	director	RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Lauren P Silvernail	officer: See Remarks	15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
David N Gill	director	C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Crystal Muilenburg	officer: Chief Marketing Officer	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Brady Stewart	director	520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660
Michael M. Jafar	officer: Chief Marketing Officer	17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614